UNSPSC 51144012: Fenisorex

This classification denotes an anorexiant with the molecular formula C16H16FNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C0P8MP2SR5, chemically known as 1h-2-benzopyran-3-methanamine, 7-fluoro-3,4-dihydro-1-phenyl-, cis- but more generally known as fenisorex, which bears US NIH Compound Identifier 36983. European Medicines Agency schedules Fenisorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07569MIG.

UNSPSC 51144012 Fenisorex is a Commodity code, but the recent state and local opportunities posted under it involve procurement of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs—a material mismatch between the code's nominal scope and actual buying activity. State and local health departments, purchasing cooperatives, and human services agencies are using this code to solicit pharmaceutical products and harm-reduction supplies, not fenisorex specifically. The issuing bodies include county health systems, state human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and government facilities.

Recent opportunities span Florida, Minnesota, Oregon, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2026, on a fixed-fee basis with an initial two-year term and one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; vendors must maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and accept a 3 percent administrative fee. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for self-insured employee health plans and state agencies, functioning as exploratory scoping before formal RFP release. The code shows inconsistent tagging against actual pharmaceutical procurement work.